Breaking News

ACM Global Relocates to Expanded Facilities

November 27, 2012

York facility offers 14,500 sq. ft. of lab and office space

ACM Global Central Lab has relocated its facilities to York, England. The larger facility offers 14,500 sq. ft. of lab and office space and accommodates ACM’s expanding lab operations, and growing staff of data analysts, project managers and quality assurance specialists.
 
“Our new facility enables us to continue our growth in the European market and to expand the menu of clinical trials testing services we offer our clients,” said Jerry Boxall, managing director, Europe at ACM Global Central Laboratory. “We are excited with the prospects offered by our new facility, which has been purpose-built to optimize our laboratory processes. The additional space enhances our ability to continue to meet the needs of our clients with high-quality laboratory services, while positioning us to take advantage of new opportunities in the market.”
 
“Expansion of our European laboratory hub represents a significant investment by our company, driven by our growth over the last several years,” said Angela J. Panzarella, president of ACM Medical Laboratory, Inc., the parent company of ACM Global Central Lab. “We have enjoyed robust growth in our European and global business, and the new facility represents our commitment to the region and to continuous improvement of the services we offer our clients.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?